Navigation Links
Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration
Date:12/14/2009

is not successful in achieving a sale of assets, restructuring, financing or any combination thereof, the Company will have to curtail or cease operations, liquidate its assets or file for bankruptcy. The Company expects to make decisions in the near future.

For additional information on Vion and its product development programs, visit the Company's Internet web site at www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion being unsuccessful in achieving its strategic alternatives, including any combination of a restructuring of the Company and its debt, a sale of the Company or its assets, and raising new capital, in which case it will curtail or cease operations, liquidate its assets or file for bankruptcy, the FDA requiring Vion to conduct a new randomized trial for Onrigin(TM) (laromustine) Injection prior to regulatory approval, Vion's potential inability to obtain regulatory approval for its products, particularly Onrigin(TM), delays in the regulatory approval process, particularly for Onrigin(TM), delays or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies, clinical trials or interim clinical trial data are not confirmed by safety and efficacy results in later or final clinical trials, the need for additional research and testing, including the need for a randomized trial of Onrigin(TM) prior to regulatory approval, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, an
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... N.J. , Aug. 28, 2015  IP Shakti, LLC, ... LLC. ... "Our new corporate identity signifies our transformation ... world,s first predictive analytics platform for patent claim validity." ... the launch of the proprietary AIA Shield™ platform, the Company ...
(Date:8/28/2015)... South Korea , Aug. 28, 2015 ... National University and Dr. Ra from Biostar , ... , Confirmed 30% increase of lifespan through multiple IV ... function, physical vitality, and life expectancy found , ... in Korea have determined the possibility that adult mesenchymal ...
(Date:8/27/2015)... Aug. 27, 2015  The Academy of Managed ... Drug Administration,s (FDA,s) draft guidance and proposed rule ... biosimilars, to bear a nonproprietary name with an ... seeking a decision from the FDA on the ... care stakeholders urging the agency to use the ...
Breaking Medicine Technology:IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2
... Inc. announced the completion of a public offering for ... of common stock and warrants to purchase up to ... proceeds of $2,592,549 in the offering. Proceeds from the offering ... Cesium-131 technology to treat lung, head and neck, breast ...
... D. Smith and Adventist Health System (AHS), one of the ... H. D. Smith will serve as the primary supply and ... long term care facilities. Under the terms ... supply chain services and support programs to Adventist Health System, ...
Cached Medicine Technology:WestPark Capital Announces $2.6 Million IsoRay Offering 2H. D. Smith and Adventist Health System Sign Prime Vendor Agreement 2H. D. Smith and Adventist Health System Sign Prime Vendor Agreement 3
(Date:8/29/2015)... ... 2015 , ... "I have been a licensed physical therapist ... in manual therapy, and my invention will provide headache sufferers a solution to ... dysfunction throughout the body." , They developed THE RELIEVER to alleviates headaches, as ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... scrotal support and protection against dribbled urine and sweat. "In order to prevent ... N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal support for ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, ... improve the lives of patients, according to a newly published report. Surviving Mesothelioma ... the full article. , The authors of the new paper focus on ...
(Date:8/29/2015)... Irvine, CA (PRWEB) , ... August 29, 2015 , ... ... on a mission. His mission is to increase acceptance of the chiropractic field ... pain medications that further debilitate them. Although Chiropractic was made available to the ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , Eau Thermale ... costs. , “Before, a threshold of $49.00 was required to qualify for free standard ... for free standard shipping for customers regardless of the item’s selling price.” , With ...
Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2
... outlines potential pharmaceutical, dietary, surgical, and other approaches ... women in the United States, and examines the ... reduction strategies for women at average risk of ... Among the recommendations: aside from following general dietary ...
... Awareness Month, SACRAMENTO, Calif., Nov. 4 Cancer ... the number one natural cause of death in,geriatric cats ... pet deaths,each year. Some breeds are especially susceptible to ... older cats and dogs, cancer also,is the most treatable ...
... Recurring Diluted FFO Per Share Increases 5.7% ... Share Increases 1.9% ... Nov. 4 Nationwide,Health Properties, Inc. (NYSE: NHP ) today announced results ... 30, 2008., "Our third quarter results continue the positive trends from the ...
... RICHMOND, Va., Nov. 4 Markel Corporation,(NYSE: MKL ... for the quarter,ended September 30, 2008 compared to diluted ... of 2007. Diluted net loss per share was $2.63 ... diluted net income per,share of $31.28 for the same ...
... 4 (Nasdaq: WHRTD ) --,World Heart ... 2008, it had received a NASDAQ Staff Deficiency ... Marketplace Rule 4310(c)(7). This rule,requires the Company to ... continued listing on the NASDAQ Capital Market. For ...
... HiArt treatment system for advanced radiation therapy, announced today that it ... Chengdu Twin Peak Accelerator Technology Inc., based in Chengdu, China. ... ... 2008 -- A linear accelerator (linac) is a key component ...
Cached Medicine News:Health News:Spot the Warning Signs of Cancer in Your Pet 2Health News:NHP Reports Third Quarter 2008 Earnings 2Health News:NHP Reports Third Quarter 2008 Earnings 3Health News:NHP Reports Third Quarter 2008 Earnings 4Health News:NHP Reports Third Quarter 2008 Earnings 5Health News:NHP Reports Third Quarter 2008 Earnings 6Health News:NHP Reports Third Quarter 2008 Earnings 7Health News:NHP Reports Third Quarter 2008 Earnings 8Health News:NHP Reports Third Quarter 2008 Earnings 9Health News:NHP Reports Third Quarter 2008 Earnings 10Health News:NHP Reports Third Quarter 2008 Earnings 11Health News:NHP Reports Third Quarter 2008 Earnings 12Health News:NHP Reports Third Quarter 2008 Earnings 13Health News:NHP Reports Third Quarter 2008 Earnings 14Health News:NHP Reports Third Quarter 2008 Earnings 15Health News:NHP Reports Third Quarter 2008 Earnings 16Health News:Markel Reports Third Quarter and Nine-Month Results 2Health News:Markel Reports Third Quarter and Nine-Month Results 3Health News:Markel Reports Third Quarter and Nine-Month Results 4Health News:WorldHeart Receives Notice From the NASDAQ Stock Market Regarding Non-Compliance With Marketplace Rule 4310(c)(7) 2Health News: TomoTherapy Completes Acquisition of Linear Accelerator Manufacturer in China 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: